AN-4005 is under clinical development by Adlai Nortye Biopharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AN-4005’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AN-4005 overview

AN-4005 is under development for the treatment colorectal cancer, head and neck cancer, melanoma, relapsed and refractory lymphoma natural killer cell lymphomas, Hodgkin lymphoma (B-cell Hodgkin lymphoma), peripheral T-cell lymphomas (PTCL) and diffuse large B-cell lymphoma. It is administered through oral route. It acts by targeting programmed cell death 1 ligand 1.

Adlai Nortye Biopharma overview

Adlai Nortye Biopharma (Adlai Nortye) is a biopharmaceutical company that discovers and develops drugs for oncology indications. The company is investigating AN2025, a trial-stage pan-PI3K inhibitor for the treatment of recurrent and metastatic head and neck squamous cell carcinoma; and AN0025, an EP4 antagonist designed against triple negative breast cancer, non-small-cell lung carcinoma, bladder, rectum and cervical cancer, and microsatellite stable colorectal cancer. It is also evaluating AN1004 to treat human epidermal growth factor receptor-2-negative metastatic breast cancer; AN4005 against advanced tumors; AN3025 and AN6025 for solid tumors. Adlai Nortye utilizes PAINT-2D and ANEAT-Id platform technologies to identify and develop immunotherapies and antibodies. The company operates research and development, clinical operation centers in China, and the US. Adlai Nortye is headquartered in Hangzhou, Zhejiang, China.

For a complete picture of AN-4005’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.